Seventy-one per cent (140 episodes) were treated successfully by air or hydrostatic enema reduction. Spontaneous de-vagination was observed on radiological studies and did not require therapeutic intervention in 19 episodes (10%) with a median age of 13 months (range: 5–24 months). Thirty-eight patients selleck chemical (19%) required surgery. At surgery, 25 patients required manual reduction only whereas 13 patients required an intestinal resection (6.7%, 95% CI 3.5%, 11.0%)). The median length of bowel resected was 10 cm (range: 2–23 cm). Patients who underwent intestinal resection were marginally younger than

those who were successfully reduced by enema (resection: median age 7 months, range: 3–23 months vs non-resection: median age 9 months, range: 2–24 months). Although the mean length of hospital stay was 2.8 days (median: 2 days; range: <1–37 days), 49% of patients were admitted for ≤1 day (n = 97). Erlotinib Patients requiring surgical intervention had a longer length of stay (median 4 days; range: 0–37 days). Full immunisation records from the Australian Childhood Immunisation Register were available for 174 (88%) patients. Twenty-three records were unavailable due to; inaccurate or

missing Medicare numbers (n = 11), overseas patients (n = 2), or the Medicare number provided returned mismatched data (n = 10). As this study period spans the period before and after the implementation of rotavirus vaccines into the National Immunisation Progam, it is not surprising that only 27 patients (16%) had received at least one dose of a rotavirus vaccine. Two patients were vaccinated

in the 30 days prior to diagnosis of intussusception. The first patient was diagnosed 27 days post dose 1 (RotaTeq®) and the second occurred 6 days post dose 2 (RotaTeq®). Both patients were vaccinated within the recommended age range. Thirteen patients had received at least one Parvulin dose of another vaccine in the 30 days prior to the diagnosis of intussusception (6.7%). Thirty patients (17%) were recorded as being “overdue” for routine vaccines or had an incomplete immunisation status at the time of diagnosis of intussusception. Twenty-two per cent of patients who received a rotavirus vaccine outside the age recommendations for administration determined at the time of the study. Evaluation of the safety of rotavirus vaccines, particularly with respect to the risk of intussusception, is recommended for countries planning to introduce rotavirus vaccines into the National Immunisation Program, particularly if the country was not involved the pre-licensure trials [6].